Recently, new tools, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), effective nutrient-stimulated hormone-based antiobesity pharmacotherapeutics, have emerged and are Food and Drug Administration (FDA) approved for the treatment of type 2 diabetes (T2D) and obesity.13 The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.